What You Should Know:
– Profusa,, a digital health company, has announced the adoption of NVIDIA technology to power a new AI-driven insight portal for continuous biochemistry monitoring.
– The portal will be used in combination with Profusa’s Lumee oxygen optical hydrogel sensors and reader system, extending the company’s AI-enabled tools to remote patient monitoring settings. Profusa anticipates an early 2026 rollout of the portal in the European Economic Area (EEA).
– Profusa believes that real-time biochemistry data across a large population is a data set currently missing for AI-enabled healthcare improvements. By combining its Lumee platform with NVIDIA NeMo hardware and software, Profusa plans to build a scalable, AI-fueled technology backbone to improve personalized sensor data accuracy and connect real-time sensor data with electronic medical records (EMR).
Redefining Healthcare with AI-Fueled Workflows
The new portal is designed to provide physicians with “trustworthy, always-on insights” rather than just more dashboards. It aims to translate raw optical signals from the sensors into reliable biometrics and provide actionable clinical context.
Expected capabilities and features of the physician portal include:
- Agentic clinical workflows: An AI-powered assistant that integrates with EMRs, wearables, and home devices to help with notes, orders, care plans, remote monitoring, and triage.
- Time-aligned health data graph: A longitudinal view that combines Profusa biomarkers with EMR data, claims, wearables, genomics, and social determinants to power predictions and coaching.
- Guardrails by design: The system will use policy-aware orchestration to enforce clinical scope, data privacy, and safe responses.
- Model training options: The platform will allow for parameter-efficient tuning and post-training refinement of Profusa’s AI signal processing and clinical reasoning components.
“We believe that real-time biochemistry data across a large population is a data-set that is currently missing to enable the fulfillment of the promise of AI-enabled improvement in healthcare. Profusa is uniquely positioned to provide this proprietary data set, linking therapeutic decisions with real-time biochemistry changes, to generate valuable insights that are lacking today.” Ben Hwang, Ph.D., Profusa’s Chairman and CEO commented, “By combining our Lumee platform with the industry leading NVIDIA NeMo hardware and software stack, we plan to build an AI-fueled, scalable technology backbone for better personalized sensor data accuracy and real-time sensor data connections with electronic medical records (EMR), facilitating treatment and outcome predictions, in addition to establishing a robust data base for clinical literature for disease management.”
